J&J's IBD combo fails Phase 2 studies, but will move into pivotal testing
Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy's failure in two mid-stage trials. The company said that JNJ-4804, a combination of the blockbuster drugs Tremfya ...
May 5, 2026 10:30 AM EDT R&D J&J's IBD combo fails Phase 2 studies, but will move into pivotal testing Max Gelman Senior Editor Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy’s failure in two mid-stage trials. The company … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that